摘要
目的评价伊立替康介入栓塞联合5-Fu/CF静脉化疗治疗结直肠癌肝转移的疗效和毒性。方法结直肠癌肝转移患者行TACE术,伊立替康(CPT-11)加超液化碘油化疗栓塞,介入完成后即行5-Fu/CF静脉化疗,每3周重复。结果全组26例患者共接受了98个周期化疗,平均4个周期(3~6周期)。CR2例(7.69%),PR8例(30.77%),SD13例(50%),PD3例(11.54%);临床获益率88.46%(23/26);中位疾病进展时间7.3月;中位生存期14.2月。最常见的毒副反应是中性粒细胞减少,消化道反应,多为Ⅰ~Ⅱ级。结论伊立替康肝动脉化疗栓塞联合CF/5-Fu静脉化疗治疗结直肠癌肝转移疗效肯定,毒性反应可以耐受。
Objective To evaluate the efficacy and toxicity of TACE using Irinotecan and lipiodol combining with intravenous CF/5-Fu in the treatment of hepatic metastasis from colorectal cancer. Methods Twenty six cases with hepatic metastasis from colorectal cancer were treated by the above-mentioned method, every three weeks was a cycle. Results Two cases had complete response, eight cases had partial response,thirteen cases had stable disease and three cases with progressive disease. Gross efficiency rate was 38. 46% and the stability rate was 50%. The clinical beneficial response rate was 88. 46%. Median time to progression was 7. 3 months and median overall survival time was 14. 2 months. The common treatment related adverse events were neutropenia and delayed diarrhea. Toxic effect was light. Conclusion TACE using Irinotecan and Lipiodol combining with intravenous CF/5-Fu in the treatment of hepatic metastasis from colorectal cancer is an effective and well tolerated regimen.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2009年第8期696-698,共3页
Cancer Research on Prevention and Treatment
关键词
伊立替康
肝转移癌
结直肠癌
介入
Irinotecan
Hepatic metastasis
Colorectal cancer
Intervention